Rodney L. Rietze

Dr. Rietze’s academic career focused on discovering the biological mechanisms that underpin the regenerative capacity of the central nervous system. In 2008, he transitioned to industry to apply these learnings to develop a novel class of therapeutics, cell and gene therapies, at the newly created Pfizer Regenerative Medicine (Cambridge, UK). He later joined Novartis, where he helped develop novel bioprocesses, analytics and enabling technologies to support the clinical development and commercial launch of KymriahTM, the first FDA-approved personalized CAR-T cell therapy. In continuation of his life-long pursuit to deliver innovative technologies and novel therapeutics to expand and transform the treatment of disease, Dr. Rietze co-founded iVexSol in 2019, where he uses his two decades of technical, operational and strategic leadership experience to guide and support an outstanding team as they work to transform the manufacture of viral vectors.

Dr. Rietze holds a B.Sc. and M.Sc. from The University of Calgary and a Ph.D. from The University of Melbourne.